Alterations in tubular epithelial cells in diabetic nephropathy

Journal of Nephrology

Volumn 26, Issue 5, 2013, Pages 865-869

  Habib, Samy L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cell matrix protein; Diabetes; Fibrosis; Tubular injury

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; TUBERIN; VIMENTIN; BIOLOGICAL MARKER; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN TISSUE; KIDNEY HYPERTROPHY; KIDNEY TUBULE CELL; EPITHELIUM CELL; FIBROSIS; KIDNEY; KIDNEY PROXIMAL TUBULE; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

BIOLOGICAL MARKERS; COLLAGEN TYPE IV; DIABETIC NEPHROPATHIES; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; FIBROSIS; HUMANS; KIDNEY; KIDNEY TUBULES, PROXIMAL; MALE; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; VIMENTIN;

EID: 84884652645     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000287     Document Type: Article

References (17)

1. Ihm CG, Lee GSL, Nast CC, et al. Early increased renal procollagen alpha 1(IV) mRNA levels in streptozotocin induced diabetes. Kidney Int. 1992; 41(4): 768-777.
2. Brito PL, Fioretto P, Drummond K, et al. Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney Int. 1998; 53(3): 754-761.
3. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984; 74(4): 1143-1155.
4. Phillips AO, Steadman R. Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol. 2002; 17(1): 247-252.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865): 813-820.
6. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003; 17(15): 1829-1834.
7. White ES, Sagana RL, Booth AJ, et al. Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Exp Cell Res. 2010; 316(16): 2644-2653.
8. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115(5): 577-590.
9. Sekulić A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000; 60(13): 3504-3513.
10. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002; 62(20): 5645-5650.
11. Longo VD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY). 2011; 3(11): 1039-1040.
12. Ong CT, Khoo YT, Mukhopadhyay A, et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol. 2007; 16(5): 394-404.
13. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2009; 20(12): 2493-2502.
14. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol. 2006; 17(11): 2992-2998.
15. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004; 15(1): 1-12.
16. Habib SL, Yadav M, Tizani S, Bhandari B, Valente AJ. Tuberin inhibits production of the matrix protein fibronectin in diabetes. J Am Soc Nephrol. 2012; 23(10): 1652-1662.
17. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 2001; 105(3): 357-368.